Workflow
SmartDose
icon
Search documents
WEST ALERT: Bragar Eagel & Squire, P.C. is Investigating West Pharmaceutical Services, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
GlobeNewswire News Room· 2025-07-09 01:00
Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against West Pharmaceutical Services, Inc. due to allegations of fiduciary duty breaches by the board of directors following a class action complaint filed on June 20, 2025 [1] Company Overview - West Pharmaceutical Services, Inc. is a medical supplies company based in Exton, Pennsylvania, serving as a key supplier to the pharmaceutical, biotechnology, and generic drug industries [2] Allegations and Issues - The class action complaint alleges that West failed to disclose significant destocking issues in its high-margin High-Value Products portfolio, despite claiming strong visibility into customer demand [2] - The SmartDose device, positioned as a high-margin growth product, was found to be dilutive to profit margins due to operational inefficiencies [2] - Margin pressures raised the risk of costly restructuring activities, including the exit from continuous glucose monitoring contracts with long-standing customers [2] - Positive statements made by the company regarding its business and prospects were claimed to be materially false or misleading [2] Disclosure of Financial Issues - The truth about the alleged fraud was revealed on February 13, 2025, when West issued weak revenue and earnings forecasts for 2025, attributing the disappointing guidance to contract manufacturing headwinds and the loss of two major customers [3] - West indicated that its SmartDose devices would be margin-dilutive in 2025 and mentioned plans to improve the device's economics [3] - Following this disclosure, West's stock price dropped by $123.17 per share, a decline of 38%, closing at $199.11 on February 13, 2025 [3]
Class Action Filed Against West Pharmaceutical Services, Inc. (WST) Seeking Recovery for Investors - Contact The Gross Law Firm
Prnewswire· 2025-07-07 13:00
NEW YORK, July 7, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of West Pharmaceutical Services, Inc. (NYSE: WST).Shareholders who purchased shares of WST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/west-pharmaceutical-services-inc-loss-submission-form/?id=155401&from=4CLAS ...
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of West Pharmaceutical Services
GlobeNewswire News Room· 2025-07-06 12:25
Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against West Pharmaceutical Services, Inc. due to allegations of misleading statements and failure to disclose significant operational issues that have negatively impacted the company's financial performance [3][5]. Group 1: Allegations Against West Pharmaceutical Services - The complaint alleges that West and its executives violated federal securities laws by making false and misleading statements regarding customer demand and operational challenges, particularly in their High-Value Products portfolio [5]. - It is claimed that West's SmartDose device, which was marketed as a high-margin growth product, actually diluted profit margins due to operational inefficiencies [5]. - The allegations include that these margin pressures could lead to costly restructuring activities, including the exit from continuous glucose monitoring contracts with long-standing customers [5]. Group 2: Financial Impact and Stock Performance - The truth about the alleged fraud was revealed on February 13, 2025, when West issued weak revenue and earnings forecasts for 2025, attributing the disappointing guidance to contract manufacturing headwinds and the loss of two major customers [6]. - Following the announcement, West's stock price plummeted by $123.17 per share, a decline of 38%, closing at $199.11 on the same day [7]. Group 3: Legal Proceedings and Investor Actions - Investors who suffered losses exceeding $100,000 between February 16, 2023, and February 12, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1]. - There is a deadline of July 7, 2025, for investors to seek the role of lead plaintiff in the federal securities class action against West [3].
WST DEADLINE: ROSEN, A LONGSTANDING FIRM, Encourages West Pharmaceutical Services, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important July 7 Deadline in Securities Class Action – WST
GlobeNewswire News Room· 2025-07-02 20:19
NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of West Pharmaceutical Services, Inc. (NYSE: WST) between February 16, 2023 and February 12, 2025, both dates inclusive (the “Class Period”), of the important July 7, 2025 lead plaintiff deadline. SO WHAT: If you purchased West common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fe ...
Investors who lost money on West Pharmaceutical Services, Inc. (WST) should contact The Gross Law Firm about pending Class Action - WST
GlobeNewswire News Room· 2025-07-02 19:59
NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of West Pharmaceutical Services, Inc. (NYSE: WST). Shareholders who purchased shares of WST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/west-pharmaceutical-services-inc-loss-submission-form/?id=155069&fr ...
WST Deadline: WST Investors Have Opportunity to Lead West Pharmaceutical Services, Inc. Securities Fraud Lawsuit
Prnewswire· 2025-06-30 18:27
NEW YORK, June 30, 2025 /PRNewswire/ --Why: New York, N.Y., June 30, 2025. Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of West Pharmaceutical Services, Inc. (NYSE: WST) between February 16, 2023 and February 12, 2025, both dates inclusive (the "Class Period"), of the important July 7, 2025 lead plaintiff deadline.So what: If you purchased West Pharmaceutical common stock during the Class Period you may be entitled to compensation without payment of any out of pocket ...
July 7, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against WST
GlobeNewswire News Room· 2025-06-26 20:33
NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of West Pharmaceutical Services, Inc. (NYSE: WST). Shareholders who purchased shares of WST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/west-pharmaceutical-services-inc-loss-submission-form/?id=154297&fr ...
WST DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages West Pharmaceutical Services, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important July 7 Deadline in Securities Class Action – WST
GlobeNewswire News Room· 2025-06-26 20:31
NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of West Pharmaceutical Services, Inc. (NYSE: WST) between February 16, 2023 and February 12, 2025, both dates inclusive (the “Class Period”), of the important July 7, 2025 lead plaintiff deadline. SO WHAT: If you purchased West common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fe ...
WST Stock Builds on GLP-1 Growth, Annex 1 and Margins in Focus
ZACKS· 2025-06-26 13:51
Key Takeaways WST is seeing strong growth from GLP-1-related high-value components and auto-injector demand. WST's Annex 1 projects are driving a favorable mix shift toward higher-margin pharma offerings. Margin pressure stems from WST's lower-margin product growth, pricing headwinds and $20-$25M in new tariffs.West Pharmaceutical Services, Inc. (WST) is well-positioned for growth, backed by the robust GLP-1 related demand and its expansion plans. However, pricing headwinds and tariff risks are concerning ...
WST Deadline: WST Investors with Losses in Excess of $100K Have Opportunity to Lead West Pharmaceutical Services, Inc. Securities Fraud Lawsuit
Prnewswire· 2025-06-25 18:58
Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of West Pharmaceutical Services, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on July 7, 2025 [1] Group 1: Class Action Details - Investors who purchased West Pharmaceutical common stock between February 16, 2023, and February 12, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by July 7, 2025 [3] - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6] Group 2: Case Allegations - The lawsuit alleges that West Pharmaceutical made false and misleading statements regarding its business operations, particularly concerning its High-Value Products portfolio and the SmartDose device [5] - Specific claims include that West was experiencing significant destocking in its high-margin products, contrary to its public statements, and that the SmartDose device was negatively impacting profit margins due to operational inefficiencies [5] - The lawsuit asserts that these misleading statements led to investor damages when the true situation was revealed [5] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements in the past, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in terms of settlements [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in representing investor interests [4]